Chugai schedules October 27 results with JPY 343.45 billion forecast for Chugai Pharmaceutical stock

Published on 10/25/2026 at 02:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached JPY 341.58 billion in 2026. Chugai Pharmaceutical stock had JPY 116.33 billion net income.

Strategic award and quarterly date

Chugai received the Porter Prize on October 16, 2026, marking the first such award for the company.
Second-quarter 2026 revenue reached JPY 341.58 billion, while net income stood at JPY 116.33 billion.
Chugai will publish third-quarter 2026 results on October 27, 2026, followed by an investor conference.
Chugai Pharmaceutical stock was last quoted at EUR 36.79 on October 22, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (ISIN JP3519400000) received the Porter Prize on October 16, 2026, recognizing its technology-led drug discovery model and strategic alliance with Roche. The award adds a corporate-strategy signal ahead of the company's third-quarter results scheduled for October 27, 2026.

Why the award matters strategically

According to Chugai Pharmaceutical, the prize recognized its proprietary drug discovery technologies, antibody engineering and SnipeTide platform. The company said its Roche alliance allows it to reinvest profits in research and development while maintaining profitability.

The latest reported operating figures provide the financial context. The Globe and Mail reported that second-quarter 2026 revenue reached JPY 341.58 billion, up from JPY 290.01 billion a year earlier, while net income rose to JPY 116.33 billion from JPY 97.16 billion. That represents revenue growth of 17.78 percent and net-income growth of 19.73 percent.

What will October 27 show?

Chugai's investor-relations calendar lists October 27, 2026, for third-quarter results covering January through September 2026, followed at 6:00 p.m. Japan time by a financial-results conference, according to Chugai Pharmaceutical. A forecast published by Finanzen.ch puts third-quarter revenue at JPY 343.45 billion and earnings per share at JPY 74.98.

Three dated developments

On October 13, 2026, Chugai reported Roche's vamikibart data through Week 52, with about two-thirds of patients in as-needed dosing requiring no retreatment, according to Chugai Pharmaceutical. On October 16, the company received the Porter Prize 2026. On October 27, it is scheduled to publish third-quarter results for the first nine months of fiscal 2026.

Key dates for investors

The next two scheduled events are both on October 27, 2026: the third-quarter results release and the conference on those results. Macquarie maintained a Buy rating and set a JPY 7,300.00 price target on October 16, 2026, as reported by Markets Insider.

Stock reference in Germany

Chugai Pharmaceutical stock was last quoted at EUR 36.79 on Börse Hamburg on October 22, 2026 at 8:19 a.m. CEST. The Tokyo-listed shares closed at JPY 6,795.00 on October 23, 2026, after a 2.74 percent session gain.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.